Sumitomo Pharma Co., Ltd. Logo

Sumitomo Pharma Co., Ltd.

DNPUF

(0.5)
Stock Price

4,30 USD

-57.74% ROA

-97.03% ROE

-0.97x PER

Market Cap.

253.064.456.702,82 USD

242.5% DER

0% Yield

-78.95% NPM

Sumitomo Pharma Co., Ltd. Stock Analysis

Sumitomo Pharma Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Sumitomo Pharma Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

2 ROE

Unidentified ROE

3 ROA

Unidentified ROA

4 PBV

Unidentified ROA

5 DER

Unidentified DER

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

Unidentified Graham Number

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Sumitomo Pharma Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Sumitomo Pharma Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Sumitomo Pharma Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Sumitomo Pharma Co., Ltd. Revenue
Year Revenue Growth
2005 175.088.000.000
2006 245.784.000.000 28.76%
2007 261.213.000.000 5.91%
2008 263.992.000.000 1.05%
2009 264.060.000.000 0.03%
2010 296.295.000.000 10.88%
2011 379.529.000.000 21.93%
2012 350.384.000.000 -8.32%
2013 347.732.000.000 -0.76%
2014 387.709.000.000 10.31%
2015 371.370.000.000 -4.4%
2016 403.205.000.000 7.9%
2017 411.645.000.000 2.05%
2018 466.838.000.000 11.82%
2019 459.267.000.000 -1.65%
2020 482.732.000.000 4.86%
2021 515.952.000.000 6.44%
2022 560.035.000.000 7.87%
2023 307.824.000.000 -81.93%
2023 555.544.000.000 44.59%
2024 314.558.000.000 -76.61%
2025 362.700.000.000 13.27%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Sumitomo Pharma Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 47.266.000.000 100%
2009 52.818.000.000 10.51%
2010 51.371.000.000 -2.82%
2011 68.159.000.000 24.63%
2012 56.890.000.000 -19.81%
2013 59.844.000.000 4.94%
2014 69.804.000.000 14.27%
2015 71.304.000.000 2.1%
2016 82.033.000.000 13.08%
2017 80.819.000.000 -1.5%
2018 86.928.000.000 7.03%
2019 102.364.000.000 15.08%
2020 115.112.000.000 11.07%
2021 132.682.000.000 13.24%
2022 94.903.000.000 -39.81%
2023 90.048.000.000 -5.39%
2023 131.858.000.000 31.71%
2024 112.637.000.000 -17.06%
2025 52.496.000.000 -114.56%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Sumitomo Pharma Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 52.404.000.000
2006 86.461.000.000 39.39%
2007 116.312.000.000 25.66%
2008 124.794.000.000 6.8%
2009 5.153.000.000 -2321.77%
2010 4.844.000.000 -6.38%
2011 4.960.000.000 2.34%
2012 5.128.000.000 3.28%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 181.668.000.000 100%
2018 183.651.000.000 1.08%
2019 180.439.000.000 -1.78%
2020 154.348.000.000 -16.9%
2021 190.373.000.000 18.92%
2022 249.081.000.000 23.57%
2023 236.612.000.000 -5.27%
2023 373.316.000.000 36.62%
2024 429.538.000.000 13.09%
2025 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Sumitomo Pharma Co., Ltd. EBITDA
Year EBITDA Growth
2005 20.094.000.000
2006 40.158.000.000 49.96%
2007 58.550.000.000 31.41%
2008 51.683.000.000 -13.29%
2009 97.422.000.000 46.95%
2010 124.996.000.000 22.06%
2011 174.816.000.000 28.5%
2012 165.238.000.000 -5.8%
2013 60.660.000.000 -172.4%
2014 68.414.000.000 11.33%
2015 41.504.000.000 -64.84%
2016 55.107.000.000 24.68%
2017 73.588.000.000 25.11%
2018 103.490.000.000 28.89%
2019 79.229.000.000 -30.62%
2020 104.172.000.000 23.94%
2021 103.110.000.000 -1.03%
2022 124.359.000.000 17.09%
2023 -59.120.000.000 310.35%
2023 -3.498.000.000 -1590.11%
2024 36.290.000.000 109.64%
2025 15.208.000.000 -138.62%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Sumitomo Pharma Co., Ltd. Gross Profit
Year Gross Profit Growth
2005 63.989.000.000
2006 115.347.000.000 44.52%
2007 161.867.000.000 28.74%
2008 164.606.000.000 1.66%
2009 160.295.000.000 -2.69%
2010 183.998.000.000 12.88%
2011 269.482.000.000 31.72%
2012 251.539.000.000 -7.13%
2013 246.038.000.000 -2.24%
2014 283.592.000.000 13.24%
2015 270.143.000.000 -4.98%
2016 298.735.000.000 9.57%
2017 311.567.000.000 4.12%
2018 354.493.000.000 12.11%
2019 345.714.000.000 -2.54%
2020 353.059.000.000 2.08%
2021 378.179.000.000 6.64%
2022 402.908.000.000 6.14%
2023 188.252.000.000 -114.03%
2023 376.625.000.000 50.02%
2024 157.079.000.000 -139.77%
2025 222.904.000.000 29.53%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Sumitomo Pharma Co., Ltd. Net Profit
Year Net Profit Growth
2005 6.924.000.000
2006 15.377.000.000 54.97%
2007 22.605.000.000 31.98%
2008 25.591.000.000 11.67%
2009 19.987.000.000 -28.04%
2010 20.958.000.000 4.63%
2011 16.796.000.000 -24.78%
2012 8.629.000.000 -94.65%
2013 10.043.000.000 14.08%
2014 20.060.000.000 49.94%
2015 15.447.000.000 -29.86%
2016 24.697.000.000 37.45%
2017 31.316.000.000 21.14%
2018 53.448.000.000 41.41%
2019 48.627.000.000 -9.91%
2020 40.753.000.000 -19.32%
2021 56.219.000.000 27.51%
2022 56.413.000.000 0.34%
2023 -115.504.000.000 148.84%
2023 -74.512.000.000 -55.01%
2024 -314.969.000.000 76.34%
2025 63.748.000.000 594.08%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Sumitomo Pharma Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 42
2006 55 24.07%
2007 57 3.57%
2008 64 12.5%
2009 50 -28%
2010 53 3.85%
2011 42 -23.81%
2012 22 -100%
2013 25 16%
2014 50 50%
2015 39 -31.58%
2016 62 38.71%
2017 79 20.51%
2018 135 41.79%
2019 122 -9.84%
2020 103 -19.61%
2021 142 27.66%
2022 142 0%
2023 -291 148.62%
2023 -188 -55.08%
2024 -793 76.39%
2025 160 595%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Sumitomo Pharma Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2005 11.884.000.000
2006 4.512.000.000 -163.39%
2007 28.114.000.000 83.95%
2008 22.865.000.000 -22.96%
2009 9.459.000.000 -141.73%
2010 20.553.000.000 53.98%
2011 45.895.000.000 55.22%
2012 39.531.000.000 -16.1%
2013 39.889.000.000 0.9%
2014 28.387.000.000 -40.52%
2015 17.885.000.000 -58.72%
2016 39.675.000.000 54.92%
2017 8.165.000.000 -385.92%
2018 81.066.000.000 89.93%
2019 35.797.000.000 -126.46%
2020 32.777.000.000 -9.21%
2021 124.795.000.000 73.74%
2022 17.745.000.000 -603.27%
2023 -48.500.000.000 136.59%
2023 -805.000.000 -5924.84%
2024 -257.623.000.000 99.69%
2025 -27.356.000.000 -841.74%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Sumitomo Pharma Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2005 15.523.000.000
2006 9.085.000.000 -70.86%
2007 37.872.000.000 76.01%
2008 32.509.000.000 -16.5%
2009 26.295.000.000 -23.63%
2010 26.682.000.000 1.45%
2011 55.041.000.000 51.52%
2012 48.382.000.000 -13.76%
2013 49.914.000.000 3.07%
2014 49.943.000.000 0.06%
2015 30.251.000.000 -65.1%
2016 49.415.000.000 38.78%
2017 21.624.000.000 -128.52%
2018 93.420.000.000 76.85%
2019 48.711.000.000 -91.78%
2020 46.128.000.000 -5.6%
2021 135.601.000.000 65.98%
2022 31.239.000.000 -334.08%
2023 -44.336.000.000 170.46%
2023 11.937.000.000 471.42%
2024 -241.893.000.000 104.93%
2025 -25.053.000.000 -865.53%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Sumitomo Pharma Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2005 3.639.000.000
2006 4.573.000.000 20.42%
2007 9.758.000.000 53.14%
2008 9.644.000.000 -1.18%
2009 16.836.000.000 42.72%
2010 6.129.000.000 -174.69%
2011 9.146.000.000 32.99%
2012 8.851.000.000 -3.33%
2013 10.025.000.000 11.71%
2014 21.556.000.000 53.49%
2015 12.366.000.000 -74.32%
2016 9.740.000.000 -26.96%
2017 13.459.000.000 27.63%
2018 12.354.000.000 -8.94%
2019 12.914.000.000 4.34%
2020 13.351.000.000 3.27%
2021 10.806.000.000 -23.55%
2022 13.494.000.000 19.92%
2023 4.164.000.000 -224.06%
2023 12.742.000.000 67.32%
2024 15.730.000.000 19%
2025 2.303.000.000 -583.02%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Sumitomo Pharma Co., Ltd. Equity
Year Equity Growth
2005 135.433.000.000
2006 288.633.000.000 53.08%
2007 306.012.000.000 5.68%
2008 318.277.000.000 3.85%
2009 324.495.000.000 1.92%
2010 343.483.000.000 5.53%
2011 323.983.000.000 -6.02%
2012 319.227.000.000 -1.49%
2013 349.247.000.000 8.6%
2014 398.539.000.000 12.37%
2015 451.021.000.000 11.64%
2016 446.471.000.000 -1.02%
2017 460.656.000.000 3.08%
2018 452.723.000.000 -1.75%
2019 498.138.000.000 9.12%
2020 632.105.000.000 21.19%
2021 648.178.000.000 2.48%
2022 673.569.000.000 3.77%
2023 406.782.000.000 -65.58%
2023 412.045.000.000 1.28%
2024 156.136.000.000 -163.9%
2025 160.929.000.000 2.98%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Sumitomo Pharma Co., Ltd. Assets
Year Assets Growth
2005 201.431.000.000
2006 392.966.000.000 48.74%
2007 382.535.000.000 -2.73%
2008 399.790.000.000 4.32%
2009 391.294.000.000 -2.17%
2010 626.743.000.000 37.57%
2011 589.868.000.000 -6.25%
2012 559.410.000.000 -5.44%
2013 607.219.000.000 7.87%
2014 659.032.000.000 7.86%
2015 711.583.000.000 7.39%
2016 707.715.000.000 -0.55%
2017 793.950.000.000 10.86%
2018 809.684.000.000 1.94%
2019 834.717.000.000 3%
2020 1.252.878.000.000 33.38%
2021 1.308.127.000.000 4.22%
2022 1.308.007.000.000 -0.01%
2023 1.134.742.000.000 -15.27%
2023 1.148.855.000.000 1.23%
2024 907.506.000.000 -26.59%
2025 868.932.000.000 -4.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Sumitomo Pharma Co., Ltd. Liabilities
Year Liabilities Growth
2005 65.998.000.000
2006 104.333.000.000 36.74%
2007 76.523.000.000 -36.34%
2008 81.430.000.000 6.03%
2009 66.799.000.000 -21.9%
2010 283.260.000.000 76.42%
2011 265.885.000.000 -6.53%
2012 240.183.000.000 -10.7%
2013 257.971.000.000 6.9%
2014 260.492.000.000 0.97%
2015 260.562.000.000 0.03%
2016 261.243.000.000 0.26%
2017 333.294.000.000 21.62%
2018 356.961.000.000 6.63%
2019 336.579.000.000 -6.06%
2020 620.773.000.000 45.78%
2021 659.949.000.000 5.94%
2022 634.438.000.000 -4.02%
2023 727.960.000.000 12.85%
2023 736.810.000.000 1.2%
2024 751.370.000.000 1.94%
2025 708.003.000.000 -6.13%

Sumitomo Pharma Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
829.49
Net Income per Share
-654.85
Price to Earning Ratio
-0.97x
Price To Sales Ratio
0.77x
POCF Ratio
-1.85
PFCF Ratio
-1.68
Price to Book Ratio
1.57
EV to Sales
1.71
EV Over EBITDA
-7.88
EV to Operating CashFlow
-4.13
EV to FreeCashFlow
-3.75
Earnings Yield
-1.03
FreeCashFlow Yield
-0.59
Market Cap
253,06 Bil.
Enterprise Value
564,74 Bil.
Graham Number
2442.47
Graham NetNet
-1297.63

Income Statement Metrics

Net Income per Share
-654.85
Income Quality
0.53
ROE
-0.97
Return On Assets
-0.3
Return On Capital Employed
-0.32
Net Income per EBT
0.95
EBT Per Ebit
2.33
Ebit per Revenue
-0.36
Effective Tax Rate
0.05

Margins

Sales, General, & Administrative to Revenue
1.08
Research & Developement to Revenue
0.3
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.6
Operating Profit Margin
-0.36
Pretax Profit Margin
-0.83
Net Profit Margin
-0.79

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-344.29
Free CashFlow per Share
-378.92
Capex to Operating CashFlow
-0.1
Capex to Revenue
0.04
Capex to Depreciation
0.39
Return on Invested Capital
-0.2
Return on Tangible Assets
-0.58
Days Sales Outstanding
82.02
Days Payables Outstanding
162.21
Days of Inventory on Hand
325.9
Receivables Turnover
4.45
Payables Turnover
2.25
Inventory Turnover
1.12
Capex per Share
34.63

Balance Sheet

Cash per Share
197,33
Book Value per Share
405,07
Tangible Book Value per Share
-648.02
Shareholders Equity per Share
404.89
Interest Debt per Share
1037.8
Debt to Equity
2.42
Debt to Assets
0.45
Net Debt to EBITDA
-4.35
Current Ratio
0.65
Tangible Asset Value
-257,45 Bil.
Net Current Asset Value
-382,10 Bil.
Invested Capital
305501000000
Working Capital
-172,54 Bil.
Intangibles to Total Assets
0.48
Average Receivables
85,65 Bil.
Average Payables
62,99 Bil.
Average Inventory
116201000000
Debt to Market Cap
1.54

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Sumitomo Pharma Co., Ltd. Dividends
Year Dividends Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Sumitomo Pharma Co., Ltd. Profile

About Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

CEO
Mr. Toru Kimura Ph.D.
Employee
4.980
Address
6-8, Doshomachi 2-chome
Osaka, 541-0045

Sumitomo Pharma Co., Ltd. Executives & BODs

Sumitomo Pharma Co., Ltd. Executives & BODs
# Name Age
1 Mr. Naoki Noguchi
Executive Officer of Corporate Governance & Communications, Vice President and Head of Corporate Communications
70
2 Mr. Koichi Kozuki
E.O. of R. Aff., Med. Sci., C.R.C. & Q.A., Senior Vice President, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Bus.
70
3 Mr. Kenji Ueno
Executive Officer, Senior Vice President and Head of Technology Research & Development Division
70
4 Motoyuki Sakai
Representative Director and Executive Vice President of Corporate Planning, Corporation Governance, HR & Accounting
70
5 Mr. Hiroyuki Baba
Mngg Executive Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off.
70
6 Mr. Yoshiharu Ikeda Ph.D.
Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & Director
70
7 Mr. Hideyuki Harada
Managing Exe. Officer of Tech. R&D Div., Manufacturing Div. and Dep. Head of Japan Bus. Unit
70
8 Mr. Toru Kimura Ph.D.
Representative Director, President & Chief Executive Officer
70
9 Dr. Shigeyuki Nishinaka Ph.D.
Managing Executive Office, Vice President and Head of Business Development & Management
70
10 Mr. Isao Shimizu
Executive Officer, Senior Vice President, Head of Drug Research Division & Senior Executive Research Director
70

Sumitomo Pharma Co., Ltd. Competitors